Higher expression of programmed cell death 4 (PDCD4) in acute myeloid leukemia is associated with better prognosis after chemotherapy
- 25 October 2023
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (12) , 3401-3412
Abstract
Acute myeloid leukemia (AML) is a common heterogeneous malignancy. Novel molecular markers aid diagnosis, patient sub-categorization, and optimal clinical decisions. Here, we explored the prognostic implications associated with the expression of the programmed cell death (PDCD) family of molecules in AML patients. Based on the findings from the TCGA and OHSU cohorts, we observed that the mRNA abundance of PDCD4 is significantly higher compared to other molecules within the PDCD family. Furthermore, high expression of PDCD4 was associated with predicted long-term patient survival in diagnosed AML patients. In the chemotherapy group, patients with high PDCD4 expression showed a tendency toward longer overall survival (OS) (P = 0.0266) and event-free survival (EFS) (P = 0.0008). High PDCD4 levels served as a favorable independent predictor for both OS and EFS in AML patients. However, subgroup analyses in the hematopoietic stem cell transplantation (HSCT) group revealed no significant difference in OS or EFS between individuals with high and low PDCD4 expression. Furthermore, in the low PDCD4 expression group, AML patients who underwent HSCT experienced improved survival outcomes (P = 0.0015), helping to mitigate the unfavorable prognosis associated with PDCD4 downregulation. Conversely, in the high PDCD4 expression group, HSCT offered a notable short-term survival advantage, while patients with high PDCD4 expression responded favorably to long-term survival through chemotherapy. Biological function enrichment showed that the expression of PDCD4 was correlated with complement and coagulation cascades, cell receptor signaling pathways, and cholesterol metabolism. The findings from this study will aid in better categorizing heterogeneous AML patients and guiding more appropriate clinical decision-making.Keywords
This publication has 34 references indexed in Scilit:
- Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cellsScientific Reports, 2019
- Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilledExpert Review of Anticancer Therapy, 2019
- Functional genomic landscape of acute myeloid leukaemiaNature, 2018
- The anti-PD-1 era — an opportunity to enhance radiotherapy for patients with bladder cancerNature Reviews Urology, 2017
- SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaNature Medicine, 2016
- KEGG: new perspectives on genomes, pathways, diseases and drugsNucleic Acids Research, 2016
- Targeting Immune Checkpoints in Hematologic MalignanciesPharmacological Reviews, 2016
- Roles of programmed cell death protein 5 in inflammation and cancer (Review)International Journal of Oncology, 2016
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Using GOstats to test gene lists for GO term associationBioinformatics, 2006